SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories to acquire US FDA-approved plant in India: Report

07 Oct 2013 Evaluate

Ranbaxy Laboratories is reportedly looking to acquire US Food & Drug Administration (US FDA)-approved manufacturing facility in India to secure its future launches and shift some of its blockbuster drug filings in an attempt to reduce risks arising out of issues with its Mohali plant.

Last month, the US drug authorities had issued an import alert on Ranbaxy’s refurbished Mohali plant, halting sales from the last remaining US-compliant plant in India, for violation of good manufacturing practices.

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

 

Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×